Last reviewed · How we verify

BeiGene — Portfolio Competitive Intelligence Brief

BeiGene (BGNE) pipeline: 4 marketed, 0 filed, 4 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

BGNE (NASDAQ) 4 marketed 0 filed 4 Phase 3 7 Phase 2 19 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tevimbra TISLELIZUMAB marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 Oncology 2025-01-01
Brukinsa BGB-3111 marketed Kinase Inhibitor [EPC] Tyrosine-protein kinase BTK Oncology 2019-01-01
Brukinsa ZANUBRUTINIB marketed Kinase Inhibitor [EPC] 2019-01-01
TEVIMBRA islelizumab-jsgr marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Other
Pamiparib capsule Pamiparib capsule phase 3 PARP inhibitor PARP1/PARP2 Oncology
BGB-A445 BGB-A445 phase 3 Bcl-2 inhibitor Bcl-2 Oncology
LBL-007 LBL-007 phase 3 Bruton's tyrosine kinase (BTK) inhibitor BTK Oncology
BGB-15025 BGB-15025 phase 3 Menin inhibitor Menin (MEN1 protein) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 4 shared drug classes
  2. · 2 shared drug classes
  3. Incyte Corp · 2 shared drug classes
  4. Pfizer Inc. · 2 shared drug classes
  5. AbbVie · 2 shared drug classes
  6. Sanofi · 2 shared drug classes
  7. Associazione Italiana per lo Studio del Pancreas · 1 shared drug class
  8. Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BeiGene:

Cite this brief

Drug Landscape (2026). BeiGene — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beigene. Accessed 2026-05-14.

Related